Taxoter as a new standard for treatment of hormone-refractory prostate cancer
https://doi.org/10.17650/1726-9776-2008-4-4-49-52
Abstract
One of the options in the treatment of hormone-refractory prostate cancer is the administration of cytostatic agents. This article addresses the Taxoter — one of the cytostatic agents. Clinical studies discussed in the article have demonstrated the high activity and efficacy of the agent which allows using it in the treatment of hormone-refractory prostate cancer.
About the Authors
I. G. Rusakov
P.A. Gertzen Moscow Research Institute of Oncology
Russian Federation
Russian Federation
B. Ya. Alekseyev
P.A. Gertzen Moscow Research Institute of Oncology
Russian Federation
Russian Federation
G. V. Vereshagina
P.A. Gertzen Moscow Research Institute of Oncology
Russian Federation
Russian Federation
A. A. Gritskevich
P.A. Gertzen Moscow Research Institute of Oncology
Russian Federation
Russian Federation
References
1. Чиссов В.И. Онкологическая заболеваемость и смертность. М.; 2008.
2. Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993;118:804—18.
3. Abrahamson P.-A. Revolutions in the management of hormone-refractory prostate cancer. Eur Urol Suppl 2003;2:1—2.
4. Stein C.A. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999;26:3—7.
5. Eisenberger M.A., Simon R., O'Dwyer P.J. et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827—41.
6. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormoneresistant prostate cancer. Cancer 1993;71:1098—109.
7. Kantoff P.W., Halabi S., Conaway M. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506—13.
8. Kish J., Bukkapatnam R. et al. The treatment challenge of hormone-refractory prostate cancer. Cancer Care 2001;8(6):487—95.
9. Tannock I.F., deWit R., Berry W.J. et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502—12.
10. Berthold D., Pond G. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 Study. J Clin Oncol 2008;26(2):242—5.
11. De Wit R., Eisenberger M.A., Tannock I.F. et al. A multicenter Phase III comparison of docetaxel prednisone (P) and mitoxantrone (MTZ) P in patients with androgen-independent prostate cancer (AIPC): secondary analysis of survival in patient subgroups. Ann Oncol 2004;15(Suppl. 3):abstr 4.
12. Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1515—20.
13. Wildiers H., Highley M.S., de Bruijn E.A., van Oosterom A.T. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213—42.
14. Anderson J., Van Poppel H., Bellmunt J. Chemotherapy for older patients with prostate cancer. BJU Int 2007;99(2):269—73.
15. Piccart M.J., Klijn J., Paridaens R. et al. Steroids to reduce the severity and delay the onset of docetaxel induced fluid retention. Eur J Cancer 1995;31A:575(Suppl 5, abstr 347).
16. Heidenreich A., Schrader A.J. The treatment of hormone-refractory prostate cancer. EAU Update Series 2003;1:40—50.
Review
For citations:
Rusakov I.G., Alekseyev B.Ya., Vereshagina G.V., Gritskevich A.A. Taxoter as a new standard for treatment of hormone-refractory prostate cancer. Cancer Urology. 2008;4(4):49-52. (In Russ.) https://doi.org/10.17650/1726-9776-2008-4-4-49-52
Views:
300
Email this article 